Our Board of Directors are passionate about improving our world health. Their volunteer work is supported by the CNS global community, and generous corporate partners.
Elad I. Levy, MD, MBA, FACS, FAHA: Chairman
Dr. Elad Levy is Professor of Neurosurgery and Radiology, L. Nelson Hopkins, MD Chairman of the Department of Neurological Surgery, Jacobs School of Medicine at Biomedical Sciences, at State University of New York at Buffalo. In 2017 he was appointed as one of 12 National Directors to the American Board of Neurological Surgery. In 2018 he was appointed Secretary to the Congress of Neurological Surgeons (CNS) Executive Committee and appointed to the 2018 American Association of Neurological Surgeons (AANS) Ethics Committee for a two year term. His most recent award in 2018 was receiving the “2018 Drake Lectureship” at the CV Section at CNS. Dr. Levy has a national and global reputation in the field of neurovascular disease, and has co-authored over 300 peer-reviewed publications, including several in the New England Journal of Medicine. He has also co-authored many published books in neurovascular disease, his most recent being “Decision Making in Neurovascular Disease” Thieme Publishers, May 1, 2018.
Ricardo J. Komotar, MD, FAANS, FACS
Dr. Komotar is Associate Professor of Neurological Surgery at the University of Miami School of Medicine. He graduated summa cum laude with a B.S. in neuroscience from Duke University, spending a year at Oxford University in England to focus on neuropharmacology. He received his medical degree from The Johns Hopkins University School of Medicine with highest honors and completed his internship and neurosurgical residency at Columbia University Medical Center/The Neurological Institute of New York, followed by a surgical neurooncology fellowship at Memorial Sloan-Kettering Cancer Center to specialize in brain tumors.
As Director of the University of Miami Brain Tumor Initiative, Director of Surgical Neurooncology at the University of Miami, Director of the UM Neurosurgery Residency Program, and Director of the UM Surgical Neurooncology Fellowship Program, Dr. Komotar’s main clinical interests are surgical and radiosurgical (Gamma Knife) treatment of primary and metastatic brain tumors, as well as meningiomas and pituitary lesions. Dr. Komotar is an internationally recognized leader in the field of brain tumors and performs nearly 700 procedures for these conditions each year using advanced cutting-edge surgical/radiosurgical techniques, making him one of the highest volume brain tumor surgeons in the world.
His research interests include clinical trial development and translational neurooncologic investigations designed to pioneer new therapies for brain tumors. Author of over 500 peer-reviewed scientific articles, book chapters, and invited editorials, Dr. Komotar has received research funding from the National Institutes of Health as well as other national and regional grants. He has served on the Executive Committee for the Congress of Neurological Surgeons and the Executive Board for the AANS/CNS Joint Section on Tumors. He is Founder and Director of the Annual Neurosurgery Charity Softball Tournament to benefit brain tumor research. He is a member of the Society of Neurooncology and reviewer for both Neurosurgery and the Journal of Neurosurgery. Dr. Komotar is also an Emmy ® nominated physician for his work on the series “Breakthrough Medicine”.
Dr. Ganesh Rao, MD: CNS President, 2018-2019
Dr. Ganesh Rao is a Professor of Neurosurgery in the Department of Neurosurgery at the University of Texas MD Anderson Cancer Center. He has been a faculty member since 2006. Dr. Rao is the recipient of numerous awards including the American Brain Tumor Society's Young Investigator Award and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Preuss Award for Excellence in Basic Neurosurgical Research. Dr. Rao's laboratory efforts are focused on modeling the genetic basis of malignant gliomas in mice and he is currently supported by the National Institutes of Health. His clinical interests include the surgical management of primary and metastatic brain tumors. He also has significant experience with the surgical management of primary and metastatic spinal column tumors. He has authored over 100 manuscripts on a wide variety of topics in neurosurgical oncology. He has been recognized by U.S. News and World Report and Best Doctors in America.
Dr. Steven Kalkanis: CNS President-Elect
Dr. Kalkanis is Professor and Chair of the Department of Neurosurgery, and co-director of the Neuroscience Institute, at Henry Ford Health System in Detroit, Michigan. Since Dr. Kalkanis became chair in 2014, the Department has grown to 32 faculty with 2 residents per year, and with a total of 7 NIH R01 grants currently in Neurosurgery. Dr. Kalkanis also serves as Medical Director of the Henry Ford Cancer Institute (HFCI). Under his leadership, HFCI has grown to a $1.2billion enterprise with 1425 employees treating more than 8,000 new cancer patients each year.
Dr. Kalkanis joined Henry Ford in 2004 after completing his neurosurgical training at Massachusetts General Hospital. He graduated with highest honors from Harvard University with the John Harvard Award, and then Harvard Medical School, where he served as Class Marshal and received the Linnane Prize for highest academic achievement.
In 2009, Dr. Kalkanis led a multidisciplinary team of experts to publish the largest set of guidelines to date on the treatment of metastatic brain tumors. He was the founding chair of the Congress of Neurological Surgeons (CNS) Guidelines Committee where he helped to spearhead ten clinical practice guidelines in a myriad of topics, and he is the vice-Chair of the AANS/CNS Joint Guidelines Review Committee. He also is a past president of the Michigan Association of Neurological Surgeons.
Dr. Kalkanis served as Chair of the AANS/CNS Section on Tumors from 2016-2018. In 2018, he was named a Director of the American Board of Neurological Surgery. Elected to the CNS Executive Committee in 2009, Dr. Kalkanis has served in numerous leadership roles, including Scientific Program Chair, Secretary, and now President-Elect.
With the goal of refining personalized medicine treatment protocols, and as the Mark Rosenblum Endowed Chair in Neurosurgery, Dr. Kalkanis runs an NIH-funded translational research laboratory investigating molecular genetic differences between short-and long-term glioma survivors. Specializing in brain tumor surgery, he has been involved in numerous clinical trials and has authored over 135 peer reviewed publications.